四项肿瘤标志物联合检测在卵巢肿瘤诊断中的应用

目的探讨端粒酶活性与三种血清肿瘤标志物即糖类抗原(CA125)、铁蛋白(SF)、人白细胞介素2受体(SIL-2R)联合检测在卵巢肿瘤诊断中的应用价值。方法对65例恶性卵巢肿瘤患者、48例良性卵巢肿瘤患者及31例正常卵巢组织进行组织中端粒酶活性及其血清中肿瘤标志物CA125、SF、SIL-2R的水平检测。结果端粒酶活性与三种血清肿瘤标志物诊断卵巢恶性肿瘤的敏感性依次为端粒酶>CA125>SF>SIL-2R;特异性依次为端粒酶>SIL-2R>SF>CA125;四种肿瘤标志物进行平行试验的敏感性大幅提高(100%),进行系列试验的特异性显著提高(97.9%);其四种肿瘤标志物阳性检出率与病理分期明显相关(P<0.05)。结论端粒酶活性与三种血清肿瘤标志物联合检测对卵巢恶性肿瘤的早期诊断、高危人群的肿瘤筛查、病理分期及临床确诊有重要意义。

Evaluation of Combined Telomerase and Tumor Markers Measurement in Diagnostic Work-up of Ovarian Cancer

Objective To evaluate combined measurement of telomerase, CA125, SF and SIL-2R in the diagnostic work-up of ovarian cancer. Methods Check up telomerase activity in the tissue and CA125, SF, SIL-2R level in the serum of 65 patients with malignant ovarian tumor, 48 patients with benign ovarian tumor, and healthy ovarian tissues from 31 normal subjects. Results The sensitivity priority of various markers to malignant ovarian tumor was telomerase activity, then followed by CA125>SF>SIL-2R; and the speciality priority of them was telomerase activity and then followed by SIL-2R>SF>CA125. The sensitivity of four tumor markers in a parallel trial was increased rapidly (100%), and the speciality of four tumor markers in a serial trial was increased obviously (97.9%).Frequency and level of four tumor markers were associated with pathologic staging. Conclusion Multiple tumor markers combined check is invaluable in the early diagnosis, ovarian carcinoma patient screening among the risk population, clinical pathologic staging and clinical prognosis.